Racette Brad A, Gross Anat, Vouri Scott Martin, Camacho-Soto Alejandra, Willis Allison W, Searles Nielsen Susan
Department of Neurology Washington University School of Medicine 660 South Euclid Avenue, Campus Box 8111 St. Louis Missouri 63110.
School of Public Health Faculty of Health Sciences University of the Witwatersrand 7 York Road Parktown 2193 South Africa.
Ann Clin Transl Neurol. 2018 May 31;5(7):870-875. doi: 10.1002/acn3.580. eCollection 2018 Jul.
We performed a population-based case-control study of United States Medicare beneficiaries age 60-90 in 2009 with prescription data (48,295 incident Parkinson disease cases and 52,324 controls) to examine the risk of Parkinson disease in relation to use of immunosuppressants. Inosine monophosphate dehydrogenase inhibitors (relative risk = 0.64; 95% confidence interval 0.51-0.79) and corticosteroids (relative risk = 0.80; 95% confidence interval 0.77-0.83) were both associated with a lower risk of Parkinson disease. Inverse associations for both remained after applying a 12-month exposure lag. Overall, this study provides evidence that use of corticosteroids and inosine monophosphate dehydrogenase inhibitors might lower the risk of Parkinson disease.
2009年，我们针对美国年龄在60 - 90岁且有处方数据的医疗保险受益人开展了一项基于人群的病例对照研究（48295例帕金森病新发病例和52324例对照），以研究使用免疫抑制剂与帕金森病风险之间的关系。肌苷单磷酸脱氢酶抑制剂（相对风险 = 0.64；95%置信区间0.51 - 0.79）和皮质类固醇（相对风险 = 0.80；95%置信区间0.77 - 0.83）均与较低的帕金森病风险相关。在应用12个月的暴露滞后时间后，两者的反向关联仍然存在。总体而言，本研究提供了证据表明，使用皮质类固醇和肌苷单磷酸脱氢酶抑制剂可能会降低帕金森病的风险。
